ARTICLE | Clinical News
BioThrax regulatory update
May 28, 2012 7:00 AM UTC
FDA approved an sBLA from Emergent to change the administration schedule of BioThrax anthrax vaccine to a 3-dose primary series of intramuscular injections at 0, 1 and 6 months followed by a booster s...